Incidence of IFN-–Induced Acute, Subacute, or Chronic Clinical Toxicity
| Symptom . | Incidence (%) Reported in General Clinical Experience46 . | Incidence (%) Range Reported in CML . | References, CML . |
|---|---|---|---|
| Acute toxicity | |||
| ‘Flulike’ symptoms | >90 | 2-63 | 17, 47 |
| Fever/chills | 80-100 | 2-100 | 10, 14, 16, 47, 48, 51 |
| Muscle, eye, bone pain, arthralgia | 50 | 9-58 | 13, 14, 39, 47, 48, 51, 55, 100, 101 |
| Headache | 40 | 2-48 | 11, 47, 48, 51 |
| Night sweats | 10 | 5 | 47 |
| Fatigue-malaise | 30-90 | 1-93 | 10, 14, 39, 47, 48, 51 |
| Subacute toxicity | |||
| Gastrointestinal disorders | 14, 48 | ||
| Anorexia | 30-60 | 5-40 | 10, 14, 47, 48, 55 |
| Diarrhea | 30 | 5-8 | 16, 47 |
| Nausea and vomiting | 20-50 | 2-33 | 10, 14, 42, 51 |
| Weight loss | 18 | 2-41 | 13, 14, 16, 42, 47, 51 |
| Psychiatrix | 30-65 | 1-18 | |
| Vertigo | 20 | ||
| Decreased mental status | 12 | ||
| Somnolence | 11 | ||
| Confusion | 8 | 10 | 47 |
| Depression/anxiety | 1-18 | 10, 21, 47, 48 | |
| Psychosis | 1 | 100 | |
| Nightmares | 5 | 47 | |
| Dermatologic effects | |||
| Desquamation | 4 | 3-5 | 19, 20 |
| Hair loss | 5-30 | 2-29 | 13, 19, 20, 47, 51 |
| Psoriasis | 1-2 | 1-2 | 17, 100 |
| Discoid exanthem | 1 | 1 | 42 |
| ENT | |||
| Dry mouth | 1-38 | 49, 51 | |
| Mucositis | 1-17 | 39, 42 | |
| Taste disturbance | 13 | 20 | 49 |
| Endocrine | |||
| Hypothyroidism | 1-38 | 21, 47, 101 | |
| Glucosuria | 1 | 10 | |
| Hepatotoxicity | 1-13 | 16, 19, 20, 21, 42 | |
| Renal | |||
| Abnormal proteinuria | 15-25 | 20 | 99 |
| Creatinine >1.5g% | 10 | 5-10 | 99 |
| Cardiopulmonary | |||
| Pericarditis | 2 | 21 | |
| Cough | 5-18 | 13, 47 | |
| Neurologic | |||
| Neuropathy/paresthesias | 2-13 | 100 | |
| Parkinsonism | 2-13 | 13, 14, 17 | |
| Chronic toxicity | |||
| Autoimmune related | |||
| Hemolysis | |||
| +ANA | 72 | 100 | |
| Raynaud’s phenomenon | 5 | 100 | |
| Connective tissue disorder | 1 | 100 | |
| Arthritis | 2 | 100 | |
| Miscellaneous | |||
| Sarcoid | 1 | 100 | |
| Infectious | 12 | 16 | |
| Hypertriglyceridemia | 39 | 17 |
| Symptom . | Incidence (%) Reported in General Clinical Experience46 . | Incidence (%) Range Reported in CML . | References, CML . |
|---|---|---|---|
| Acute toxicity | |||
| ‘Flulike’ symptoms | >90 | 2-63 | 17, 47 |
| Fever/chills | 80-100 | 2-100 | 10, 14, 16, 47, 48, 51 |
| Muscle, eye, bone pain, arthralgia | 50 | 9-58 | 13, 14, 39, 47, 48, 51, 55, 100, 101 |
| Headache | 40 | 2-48 | 11, 47, 48, 51 |
| Night sweats | 10 | 5 | 47 |
| Fatigue-malaise | 30-90 | 1-93 | 10, 14, 39, 47, 48, 51 |
| Subacute toxicity | |||
| Gastrointestinal disorders | 14, 48 | ||
| Anorexia | 30-60 | 5-40 | 10, 14, 47, 48, 55 |
| Diarrhea | 30 | 5-8 | 16, 47 |
| Nausea and vomiting | 20-50 | 2-33 | 10, 14, 42, 51 |
| Weight loss | 18 | 2-41 | 13, 14, 16, 42, 47, 51 |
| Psychiatrix | 30-65 | 1-18 | |
| Vertigo | 20 | ||
| Decreased mental status | 12 | ||
| Somnolence | 11 | ||
| Confusion | 8 | 10 | 47 |
| Depression/anxiety | 1-18 | 10, 21, 47, 48 | |
| Psychosis | 1 | 100 | |
| Nightmares | 5 | 47 | |
| Dermatologic effects | |||
| Desquamation | 4 | 3-5 | 19, 20 |
| Hair loss | 5-30 | 2-29 | 13, 19, 20, 47, 51 |
| Psoriasis | 1-2 | 1-2 | 17, 100 |
| Discoid exanthem | 1 | 1 | 42 |
| ENT | |||
| Dry mouth | 1-38 | 49, 51 | |
| Mucositis | 1-17 | 39, 42 | |
| Taste disturbance | 13 | 20 | 49 |
| Endocrine | |||
| Hypothyroidism | 1-38 | 21, 47, 101 | |
| Glucosuria | 1 | 10 | |
| Hepatotoxicity | 1-13 | 16, 19, 20, 21, 42 | |
| Renal | |||
| Abnormal proteinuria | 15-25 | 20 | 99 |
| Creatinine >1.5g% | 10 | 5-10 | 99 |
| Cardiopulmonary | |||
| Pericarditis | 2 | 21 | |
| Cough | 5-18 | 13, 47 | |
| Neurologic | |||
| Neuropathy/paresthesias | 2-13 | 100 | |
| Parkinsonism | 2-13 | 13, 14, 17 | |
| Chronic toxicity | |||
| Autoimmune related | |||
| Hemolysis | |||
| +ANA | 72 | 100 | |
| Raynaud’s phenomenon | 5 | 100 | |
| Connective tissue disorder | 1 | 100 | |
| Arthritis | 2 | 100 | |
| Miscellaneous | |||
| Sarcoid | 1 | 100 | |
| Infectious | 12 | 16 | |
| Hypertriglyceridemia | 39 | 17 |
Acute toxicity, symptoms developing 1-24 hours after start of therapy; Subacute toxicity, symptoms developing days to 4 weeks after start of therapy; Chronic toxicity, >4 weeks after start of therapy.